

Index

- abdominal ionizing radiation,
 see radiotherapy
- abnormalities, children's health
 outcomes, *see* congenital
 abnormalities
- acetamide, 26–27, 18, 19–20
- acquired immunodeficiency syndrome
 (AIDS), 46
- activin A, 205, 208
- addonitol, 27–28
- adolescents with cancer, 63–69, 195–196
- AID (artificial insemination by donor),
 46, 48
- alcohols, 27
- alkylating agents, 57–58, 189
- amide cryoprotectants, *see* acetamide;
 formamide; methanamide
- anejaculation, 48–49
- angiogenesis, transplantation and, 191,
 225
- angiogenic granulation tissue, 221
- animal breeding
 electroejaculation use, 48
 sperm cryopreservation, 39–40, 41
- animal studies
 follicle culture, 200, 204
 McGill Cryoleaf efficacy, 148
 ovarian grafts, 219
 ovarian tissue grafts, 218
 whole ovary cryopreservation,
 233–234, 242, 245–248
- anonymity, sperm donors, 46–47
- anti-Müllerian hormone
 folliculogenesis, 200–201, 205, 207
 ovarian tissue transplantation, 224,
 226
- antioxidant treatment, 220
- antral follicles
 in vitro development, 208
 puncture, 213, 214
- apoptosis, culture conditions,
 206–207
- aquaporins, 17
 aquaporin 3, 18
 early embryos (mouse), 20
 morulae (mouse), 19, 20
- oocytes (mouse), 17–18
- aqueous solutions, 3
- arabinose, non-penetrating CPAs, 29
- Arrhenius activation energy, 17
- ART (assisted reproductive
 technology)
 CPA use, 25, 33
 embryo cryopreservation, 67
 ice crystal prevention, 12
 outcomes, 178–182, 179
 adverse effects, 182
 after oocyte cryopreservation, 178
 babies' neonatal development, 182
 multiple pregnancy, 67–68
 sperm cryopreservation, 40
 vitrification roles, 131
- artificial insemination by donor (AID),
 46, 48
- artificial shrinkage, blastocele, 99–100,
 101
- aseptic vitrification, 158–159, 165
 blastocysts, 106–107, 109–112,
 163–164
 applications, 108–109
 outcomes, 110
 protocols, 109
 cooling speed, 106–107
 embryo carrier devices, 107
 hermetically sealed, 106–107
 illustrated, 158, 159
 GV oocytes, *see* germinal vesicle
 oocytes
 outcomes, 109
 protocols, 108, 159
 solutions, 108
 vs. non-aseptic vitrification, 108–109
- assisted reproductive technology, *see*
 ART
- asthenozoospermia, 48
- autoimmune diseases, 40, 151–152, 190
- autotransplantation, *see* transplantation
- azoospermia, 57–58
 sperm retrieval, 51, 52–53
- bacterial agents, risk, 139
- basal culture conditions, 204
- basic fibroblast growth factor, 205
- biochemical pregnancies, 178
- biological carriers, sperm
 cryopreservation, 53–54
- biomaterials, ownership and
 disposition, 253–254
- biopsy
 blastocysts, 102
 embryos, 70, 81, 90
- biospectroscopy, 123
- Biot–Fourier equation, 159
- blastocetes, 95–96
 shrinkage, 99–100, 101, 111
- blastocyst aseptic vitrification,
 106–107, 109–112, 163–164
 applications for, 108–109
 in vitro development for, 109–110
 outcomes, 110
 protocols, 108, 109
- blastocyst cryopreservation, 95
 methods, 97–99
 optimal stage for, 82, 96
 pregnancy outcomes, 95
 selection, 72
 slow freezing, 99
 water/CPA movement, 21
- blastocyst vitrification, 99
 carrier devices, 107
 Cryoloop, 98
 Cryotop, 98, 100, 102
 electron microscopy grid, 97
 culture methods, 96–97
 in vitro development, 108–109, 162
 optimal stage for, 100–101, 102, 164
 pregnancy rates, 160
 protocol, 69
 rapid freezing, 157–158
 selection for, 70, 77, 111
 structural features, 95–96
 two-step treatment, 21
- blastocysts
 after thawing, 101
 bovine, 31
 cooling rate and outcomes, 89
 cryodamage, 71
 for transfer, 100–101

Index

- advantages, 97, 157
- disadvantages, 96, 97
- murine, 17, 18
- blastomeres, 95
- cryodamage to, 71
- in embryo selection, 91, 93
- in oocyte quality, 123
- bone morphogenetic proteins, 200–201, 205
- boys
 - cancer, 58
 - prepubertal, 59–61
- BRC-ABL* detection, 229
- breast cancer, 151, 190
- 1,3 butanediol (butylene glycol), 27
- butylene glycol (1,3 butanediol), 27
- cancer patients, xi
 - adolescents, 63–69, 195–196
 - ART outcome, 184
 - embryo cryobanking, 68, 251
 - evaluation for fertility preservation, 223
 - fertility preservation, 190–191
 - female, 68
 - fertility preservation options, 62–63, 190–191
 - gonadotoxic therapies, 189–190
 - oocyte cryopreservation, 150–153, 251
 - ovarian stimulation, 144–145
 - ovarian tissue cryobanking, 189, 190, 213, 218, 221
 - evaluation for transplantation, 228
 - histological analysis, 215–216
 - indications for, 190
 - safety of, 226–229
 - storage protocol, 221–222
- pregnancy complications after treatment, 251
- pre-transplantation evaluation, 222
- primordial follicle cryopreservation, 200
- recurrence risk
 - ovarian tissue autotransplantation, 252
 - SSC contamination, 62
 - whole ovary transplantation, 195
- sperm cryobanking, 40, 46, 51
- SSC transplantation, 59–61
- treatment delay, 251
- treatment planning, 58–59
- young patients, 59, 63–68, 248, 252–253
- cancer susceptibility genes, 253
- carrier devices, 133, 146
- oocyte vitrification, 132–135, 133
 - effectiveness, 134–135
 - safety, 138–139
- sperm cryopreservation, 53–54
- see also* embryo carrier devices; McGill Cryoleaf
- cell membrane permeability, 4, 10–11, 16
- cryobiological property, 16
- cryoinjury and, 10–11
- developmental changes, 21
- measurement, 16–17
- penetrating CPAs, 25
- transport channels, 4, 10–11, 17
- cell membranes, integrity, 161
- cells
 - cryoinjury, 1–2, 4
 - permeability, 4
 - proliferation in vitro, 207
- channel diffusion, 16, 17
- early embryos, 20
- morulae, 16–22, 19, 20
- oocytes and morulae, 17
- chemotherapy, *see* gonadotoxic chemotherapy
- childhood cancer, 57, 63–68, 248
 - ovarian tissue cryopreservation, 189, 252–253
 - sperm cryopreservation, 58–59
 - testicular tissue cryopreservation, 59
- children, from oocyte
 - cryopreservation, 127–128, 132
- chilling, cryobiological property, 16
- China, donor sperm cryopreservation, 46–48
- choline-based freezing media
 - MII spindle maintenance, 124–125
 - oocyte cryopreservation, 116, 122–123
- chromatin abnormalities, 163
- chromosomal abnormalities, 180–181
- classic technique
 - slow-freezing oocytes, 115, 116
 - sperm cryopreservation, 41
- cleavage stage embryo
 - cryopreservation, 68–69, 70
- comparative studies, 81–82, 96
 - vs. blastocyst, 102
 - vs. pronuclear, 82
- cryodamage, 71
- day 2, 81–82, 89, 90
- day 3, 89, 90
- selection for, 71–72, 77
- clinical assisted reproduction, *see* ART (assisted reproductive technology)
- co-culture, blastocyst cryopreservation, 95
- colligative properties, 4
- concentration, in CPA toxicity, 31–32
- congenital abnormalities
 - ART and, 179–181, 180
 - oocyte cryopreservation and, 127–128, 183–184
- consent, *see* informed consent
- contamination risk, in vitrification, 84, 98–99, 158
- cooling rate
 - and ice formation, 11
 - aseptic vitrification, 106–107, 160
 - carrier devices and, 135–137
 - danger zones, 13
 - developmental stage and outcomes, 89
 - donor egg bank protocol, 172–173
 - minimum volume cooling protocol, 172–173
 - phase diagram for CPAs, 12–14
 - slow-cooling cryopreservation, 77, 121
 - vitrification, 14, 92, 134, 137–138
 - whole ovary cryopreservation, 243
- cortical tissue, *see* ovarian cortical tissue
- CPAs (cryoprotectants), 24, 25, 33
 - animal model studies, 148
 - aseptic vitrification, 106–107, 110–112, 158
 - blastocyst cryopreservation, 99
 - aseptic vitrification, 110–111
 - slow-freezing, 99
 - vitrification, 99
- cell permeability to, 12
- combination, 13–14
- concentrations of, 14, 137 172
- cryodamage reduction, 31
- embryo cryopreservation, 68–69, 76, 91
 - vitrification, 84
- history of, 4–5
- hypothetical solution, 13
- introduction, 24
- mechanism of action, 5, 8
- movement pathway, 18
- oocyte cryopreservation
 - slow cooling, 10, 121, 122
 - vitrification, 134, 139, 140, 145
- ovarian tissue cryopreservation, 191
- ovary (whole) cryopreservation, 242–243
- permeability, 16–17, 20, 21
- phase diagram for, 12–14, 13
- selection of, 16
- slow-freezing cryopreservation, 99, 191
- sperm cryopreservation, 41

Index

- CPAs (cryoprotectants) (*cont.*)
 structures, 6
 toxicity, 7
 assessment issues, 31
 cryobiological property, 16
 factors in, 7, 31–32
 risk reduction, 13–14, 32, 134, 145
 vitrification, 99, 148, 160
 concentration in, 14, 84
 without CPAs, 41
 zona pellucida manipulation, 102
see also non-penetrating
 cryoprotectants; penetrating
 cryoprotectants
- cryobanking, 213–214
 disease transmission risk,
 139
 donor eggs, 175
 long-term, 72
 ovarian stem cells, 213–214
 ovarian tissue, 213–214
 pronuclear stage embryos, 77
 safety considerations, 72, 84
 sperm, 46
 storage containers, 90
 transportation to, 213
- cryobiology, 1–4, 7–8
 cryodamage, 16
 in cryopreservation protocols, 24
 in developmental stages, 21–22
- cryodamage, 4, 24
 and outcomes, 90
 blastocysts, 71, 99–100
 cryobiology of, 16
 egg banks and, 169–170
 embryos, 16, 70–71
 membrane permeability and,
 10–11
 oocytes, 16, 120–121
 testing for, 79–80
- Cryoleaf, 132, 134
- Cryolock, 132, 134, 172–173
 in thawing protocol, 173
- Cryoloop, 92, 106, 132, 133
 blastocyst vitrification, 98
 cooling/warming rates, 135–137
 oocyte vitrification, 133
 sperm vitrification, 48
- cryopreservation, 8
 cooling rate and danger zones, 13
 indications for, 1, 24, 78–80
 in nature, 1
 options for, 190–191
 outcomes, 90
 slow cooling, history, 10
 stress of, 79–80
 timing in, 77
 toxicity avoidance, 32
 water/CPA movement pathways,
 20–21
 cryopreservation straws, 133, 135–137
 see also cut standard straws (CSS)
 cryoprotectants *see* CPAs
 cryostability evaluation, 158
 cryostorage, *see* cryobanking
 Cryotip, 98, 132, 133
 Cryotop, 106, 132, 133
 blastocyst vitrification, 98, 100, 102
 cooling/warming rates, 135–137
 MII spindle maintenance, 124–125
 oocyte vitrification, 134
 outcomes, 102
 crystal formation, 4
 cultural issues in cryopreservation,
 174–175, 251
 culture containers, in vitro follicle
 culture, 204
 culture duration, clinical efficacy, 127
 culture media, 204–206,
 205, 208
 culture system
 blastocysts, 96–97
 follicles, 204–206, 206–207
 cumulus–oocyte complexes, 146
 cut standard straws (CSS), 158, 165
 blastocysts, 163–164
 cooling/warming rates, 135–137
 development of, 158–159
 illustrated, 158, 159
 cyclophosphamide, 189, 190
 cytoplasm, fluorescent staining, 206
 cytotoxic chemotherapy, *see* gonadotoxic
 chemotherapy
- danger zones, cooling rate and, 13
 dehydration, 1–2, 122
 intracellular, 12
 role of CPAs, 121
 slow-cooling method, 121, 122
 in whole organ cryopreservation,
 243
- developmental ability, zygote initial
 score, 162
- developmental delay, ART babies, 182
- developmental stages
 choice for cryopreservation, 90, 96
 cryopreservation procedures, 16
 for embryo transfer, 96
 permeability changes, 16–22, 18,
 20, 21
- dextran, 30
- diffusion (facilitated), *see* channel
 diffusion
- diffusion (simple), 16, 17
 early embryos (mouse), 20
 oocytes (mouse), 18, 20
- dilution procedure, 141
- dimethyl sulfoxide (DMSO), 19–20,
 25–26
 aquaporin 3 transport, 18
 aseptic vitrification, 158
 blastocyst cryopreservation, 163–164
 combined CPAs, 13–14, 139
 cooling/warming rates, 89, 157
 embryo cryopreservation, 68, 76, 139
 oocyte cryopreservation, 139, 145, 160
 properties of, 5–6
 structure, 6
 toxicity, 31
 vitrification, 139, 160, 163–164
- directional freezing, 244–245
- disaccharides, 28, 29
- disease transmission risk, vitrification,
 138–139
- DMSO, *see* dimethyl sulfoxide
- DNA integrity
 follicle viability, 206–207
 sperm cryopreservation, 48, 54
- doctors, influence of, 249
- donor programs
 donation defined, 175
 egg donation, 171
 oocyte vitrification, 169–170, 174,
 175–176
 egg bank, 172
 protocol, 172–173
 restrictions on, 175
 semen cryopreservation, 48
 sperm cryopreservation, 46
- donor–recipient synchronization, 169
- donor selection, 170
 criteria, 47, 170
 for recipient, 173
 medical tests, 171
- double fertility preservation, 213
- early embryo cryopreservation, 20–21
 see also cleavage stage embryo
 cryopreservation
- early-stage follicle culture, 205–206
- ectopic pregnancy, 179, 183
- EG, *see* ethylene glycol
- egg banks
 cryopreservation, 169–170
 donations, 174, 175
- egg donation, *see* oocyte donation
- egg yolk-citrate buffer, 41
- ejaculation, induced, 53
 see also masturbation
- ejaculatory dysfunction,
 electroejaculation therapy,
 48–49
- electroejaculation, 48–49, 53
- electron microscopy grids, 132, 133

Index

- blastocyst vitrification, 97
 cooling/warming rates, 135–137
 embryo vitrification, 106
 oocyte vitrification, 133, 134
 embryo biopsy, *see* biopsy, embryos
 embryo carrier devices, 106, 132–135, 133
 aseptic vitrification, 107
 effectiveness, 134–135
 hermetically sealed, 106–107
 non-aseptic, 107
 see also Cryoleaf; Cryolock; Cryoloop; Cryotop; cut standard straws; electron microscopy grids; Vitrisafe
 embryo cryopreservation, 70, 72, 76
 see also cleavage stage embryo cryopreservation; pronuclear stage embryo cryopreservation
 cooling rate, 77
 CPAs in, 16–17, 20–21, 26, 139
 cryodamage, 16
 day 3 and day 4, 90–92
 ethical issues, 144, 250–252
 evaluation, 158
 gonadotoxic chemotherapy, 68, 190–191
 treatment delay, 190–191, 251
 in ART, 67–68, 89, 93, 102
 legal issues, 114
 methodology, 68–69
 outcomes, 69–72, 79–80, 90, 163
 embryo survival, 68
 prognostic factors, 163
 religious objections, 114
 slow-freezing technique, 92
 volume change measurement, 17
 vs. fresh embryos, 102
 vs. oocyte cryopreservation, 114, 128
 water movement in, 16–17, 20–21
 embryo cryopreservation (animals), 76
 non-penetrating CPAs, 29, 30
 penetrating CPAs, 28
 embryo cryostorage, indefinite, 255
 embryo donation, 89, 109, 254–255
 embryo selection
 for cryopreservation, 69–70, 90, 91
 for transfer, 70, 71–72, 93
 developmental stages, 90, 93
 endometrial receptivity, 111
 grading, 147–148
 oocyte numbers thawed, 126
 oocyte quality, 123
 embryo transfer (ET)
 biopsied embryos, 81
 cleavage stage *vs.* blastocysts, 96, 102
 day 6 stage blastocysts, 100–101
 fresh *vs.* cryopreserved, 80, 102
 in vitro fertilization and, 67, 102
 oocytes GV stage *vs.* mature, 116, 147–148
 pronuclear stage, 80–81
 pronuclear *vs.* blastocysts, 81–82, 96
 pronuclear *vs.* early cleavage stages, 82
 embryonic stem cells, 62, 254–255
 embryos
 cleavage rate, 54
 disposal, 254
 embryonic stem cell harvesting, 254–255
 implantation, 81
 ownership, 254–255
 permeability changes, 21
 embryos (rodent)
 1-cell, 17, 20
 2-cell, 16, 17, 20
 4-cell, 17
 CPA permeability, 18, 20
 non-penetrating CPAs, 30–31
 penetrating CPAs, 26–27, 26
 water movement pathway, 17–18
 endocrine activity, *see* hormone levels
 endometrial preparation, 109
 for blastocyst transfer, 101, 109, 111
 for embryo transfer, 81, 173
 ovarian tissue transplantation, 226
 endometriosis, 152, 190
 environmental contamination,
 vitrification risk, 138–139
 environmental factors, in
 transplantation results, 220
 enzymatic digestion, follicular
 isolation, 195, 196, 201–204
 epidermal growth factor, 205
 epididymal sperm, 52, 54
 equilibration, 7
 cooling rate and, 137
 donor egg bank protocol, 172–173
 in pre-freeze stage, 76–77
 slow-freezing technique, 91
 vitrification, 92, 100
 oocytes, 137–146
 equilibration solution (ES), 140, 146
 estradiol, 207, 226
 estrogen levels, 207, 224
 estrogen–progesterone administration, 221
 ethanamide, *see* acetamide
 1,2 ethandiol, *see* ethylene glycol (EG)
 ethanol, 28
 ethical issues
 embryo donation, 254
 fertility cryopreservation, 248–253, 253–255
 long-term cryostorage, 72, 255
 ovarian transplantation, 195–196
 sperm cryopreservation, 43
 testicular tissue cryopreservation, 62
 young cancer patients, 62–63, 248, 249–250
 ethylene glycol (EG), 27
 aseptic vitrification, 158
 blastocyst vitrification, 160, 164
 combined CPAs, 13–14, 139
 embryo cryopreservation, 139
 mechanism, 18, 19
 oocyte cryopreservation, 139, 145
 vitrification, 139, 146, 160
 properties of, 6–7
 structure, 6
 toxicity, 7, 122
 exposure time, CPA toxicity, 31–32
 extracellular ice formation, 12, 120–121
 extracellular matrix, 204
 facilitated channel diffusion, *see* channel diffusion
 fallopian tube cryopreservation, 237–238
 families, future effects of donor programs, 175
 Family Law Reform Act (1969) UK, 249
 family lineage preservation, 249
 female age, *see* maternal age
 fertility impairment, xi
 fertility preservation, xi
 fertility restoration
 future possibilities, 62
 ovarian tissue transplantation, 223–225, 226
 SSC transplantation, 59–61
 fertilization
 cryopreservation complications, 42–43
 frozen–thawed oocytes, 126, 147
 frozen–thawed sperm, 54
 fetal hearts, assessment, 126
 fetal ovaries, follicle culture, 201, 207, 208
 fetal sacs, assessment, 126
 fibroblast growth factor (bFGF), 205
 Ficoll, 30
 fluorescent microscopy, 206
 follicle-stimulating hormone (FSH)
 after ovarian tissue graft, 193, 224, 226
 in culture media, 205

Index

- follicles
 apoptosis in culture, 206–207
 ischemic loss in transplantation, 194
 isolation techniques
 enzymatic digestion, 195, 196, 201–204
 mechanical, 201–204
 ovarian tissue sources, 201, 206
 ultrastructure, 206
 follicular culture, 208–209
 difficulties, 195, 208–209
 evaluation methods, 206–207
 hormone production, 207
 outcomes, 207–208
 publications on, 202–213
 follicular development
 assessment, 206
 ischemia and, 219–220
 ovarian tissue grafts, 194, 226
 sites, 191, 220, 225
 ovarian transplantation, 245
 follicular viability
 determination, 206
 whole ovary cryopreservation, 195, 235–236, 237
 whole ovary transplantation, 234
 folliculogenesis
 after ovarian tissue graft, 193
 control of, 200–201
 forearm, graft sites, 223–225
 formamide, 26
 fragmentation, in embryos, 163
 freeze–thaw damage, *see* cryodamage
 freezing devices, programmable, 235, 237
 freezing point, CPAs in lowering, 5
 freezing rate, *see* cooling rate
 freezing, cell damage in, 1–2
 fresh vs. frozen embryo transfer, 80, 102
 friend/relative, gamete donation, 169
 FSH, *see* follicle-stimulating hormone
 functional evaluation
 follicular growth, 207
 of oocytes, 123
 functional lifespan
 ovarian tissue transplantation, 233, 241–242
 ovary (whole) cryopreservation, 245
 fungi, cryostorage risk, 139
 galactose, 28
 gamete donation, program options, 169
 see also embryo donation; oocyte donation; sperm donation
 gamete donors
 genetic screening, 47
 health screening, 139
 gametes
 cryobank storage, 213–214
 informed consent for minors, 250
 ownership and disposition, 253–254
 gene expression, cultured follicular growth, 207
 genetic abnormalities
 continuation, 253
 oocyte donation needed, 169
 genetic screening, *see* pre-implantation genetic diagnosis (PGD)
 genital surgery, 40
 genitourinary health checks, 47–48
 germ cells, 59
 germinal vesicle (GV) oocytes, 116–117, 160, 213
 aseptic vitrification, 160, 213
 cryopreservation
 difficulties, 144
 immature oocyte, 116–117
 transportation to cryobank, 213
 vitrification, 117, 148, 160
 glass state, 11, 13–14
 glass transition temperature (T_g), 2–3
 glial cell-derived growth factor, 61
 glucose, 28
 glycerol, 27
 embryo cryopreservation, 76, 139
 gamete cryopreservation, 139
 in water movement pathway, 18–19
 oocyte cryopreservation, 145
 properties of, 5
 sperm cryopreservation, 41
 structure, 6
 toxicity, 31–32
 gonadal dysgenesis, 169
 gonadal tissue cryopreservation, 253–254
 gonadotoxic chemotherapy
 autoimmune disorders, 151–152
 embryo cryopreservation, 68
 in childhood, 57–58
 sperm cryobanking, 40, 46, 51
 toxicity of individual agents, 189, 190
 treatment planning, 40, 58–59, 233
 gonadotoxic radiotherapy, *see* radiotherapy
 gonadotropin, 221, 226
 grafted ovarian tissue, 218
 growth differentiation factor, 200–201, 207
 growth factor-supplemented media, 204, 207
 GV oocytes, *see* germinal vesicle (GV) oocytes
 gynecological malignancy, 190
 health outcomes, children of fertility preservation, 127–128, 253
 heart cryopreservation, 245
 heart malformations, babies of fertility preservation, 180, 183
 heat transfer
 ultra-rapid warming, 159
 whole ovary, 242–243, 244–245
 hematological disease
 malignant, 151, 190, 226–229
 non-malignant, 190
 hemi-straw embryo carrier, 107, 132
 cooling/warming rates, 135–137
 hepatitis A/B/C, 42, 84
 HEPES-buffered media, 139
 heterotopic transplantation
 ovarian tissue, 193–194, 218–219, 223
 sites, 220, 223–225
 histological analysis
 follicular development, 206
 ovarian tissue, 215, 226
 Hodgkin's lymphoma
 oocyte vitrification, 151
 ovarian tissue cryobanking, 192, 229
 homosexual couples, 174–175
 hormone levels
 after ovarian tissue graft, 192, 193, 194, 219, 224
 monitoring, 224, 226
 sites, 218–219
 after whole ovary transplantation, 234
 in vitro follicle growth, 207
 hormone stimulation, oocyte harvesting, 171, 184
 hormone therapy, endometrial preparation, 101, 109, 147, 173
 Human Fertilisation and Embryology Act (HFEA) UK, 249, 250, 253
 human immunodeficiency virus (HIV), 42, 47, 84
 hyaluronan, 31
 hydraulic conductivity (or coefficient), 10
 hydrostatic pressure, polyvinyl alcohol and, 13
 hypothalamic gonadotropin-releasing hormone pulse generator, 200–201
 ice formation, 1–2, 10–11
 extracellular, 12, 120–121
 intracellular, 7, 12, 24–25, 120–121
 optical differences, 12
 prevention by CPAs, 24–25, 28, 120–121

- solubility and, 4
 temperature change rate, 11, 120–121
- ice, nature of, 2
- ICSI, *see* intracytoplasmic sperm injection
- imaging, cancer patients, 228
- imide CPAs, *see* formamide; methanamide
- implantation rates
 after embryo cryopreservation, 71–72
 after oocyte cryopreservation, 126, 127
 day 6 stage blastocysts, 100–101
 success prediction, 71–72, 162
- in vitro culture
 follicles, 201–204, 207–209, 212–213
 ovarian cortical tissue, 201–204
 ovarian tissue, 214, 215–216
 SSC expansion, 61
 zygote post-thawing integrity and, 161
- in vitro fertilization (IVF)
 blastocyst cryopreservation, 95
 congenital abnormality, 179–181
 cryopreservation in, 24
 embryo transfer, 67
 embryo selection, 70
 outcomes vs. ICSI, 80–81
 embryos, 89
 donation, 254
 multigestation pregnancy reduction, 67–68, 76
 ownership, 254
 oocyte cryopreservation, 120, 125
 outcomes, 102, 125
 ovarian hyperstimulation syndrome risk, 78–79
 sperm donation, 48
 sperm harvesting, 49, 51
 surfactants, 30
- in vitro maturation (IVM)
 blastocyst vitrification, 108–110, 111
 follicles, 206
 GM stage oocytes, 148
 GV stage oocytes, 116–117, 144–145, 213
 oocyte vitrification, 148–150, 151
 primordial follicles, 200–201, 195
- infectious disease/infective agents
 cryostored embryos, 72
 embryo vitrification, 84
 oocyte vitrification, 138–139
 sperm cryopreservation, 42
 sperm donor screening, 47–48
see also aseptic vitrification
- infertility,
 embryo donation, 254
 IVF patients, 108–109
 treatment, 72
 young boys, 63–58, xi
see also cancer patients; gonadotoxic chemotherapy; premature ovarian failure
- informed consent
 donor egg programs, 175
 donor sperm, 47
 embryo cryopreservation, 72, 251
 long-term cryostorage, 72
 oocyte cryopreservation, 252
 ovarian cryopreservation, 195–196
 ovarian tissue cryopreservation, 252–253
 parental consent, 251
 sperm cryobanking, 43, 248–249
 two-stage process, 250
 validity, 72
 young patients, 62, 250, 252–253
- inhibin B levels, 224, 226
- insect breeding, sperm cryopreservation, 39–40
- insulin, 205
- insulin-like growth factor (IGF), 205
- intracellular dehydration, 12
- intracellular ice formation, 7, 12, 24–25, 120–121
- intracytoplasmic sperm injection (ICSI)
 congenital abnormality, 179–181
 donor program, 173
 oocyte cryopreservation, 116
 semen samples for, 58
 sperm cryopreservation, 48, 53–54
 sperm retrieval, 51
 testicular sperm, 54
 testicular tissue, germ cells from, 58, 59
 vs. IVF in outcomes, 80–81
- intrauterine insemination, 40, 42
- ipsigeneic germ cell transplantation, 59
- ischemia
 follicular development following, 219–220
 ovarian tissue transplantation, 233, 241–242
 ovary transplantation, 194
 ovary vitrification, 236
- isolated follicles
 early-stage, culture, 205–206
 enzymatic digestion, 195, 196
 primordial, in vitro maturation, 195
- IUI (intrauterine insemination), 40, 42
- IVF, *see* in vitro fertilization
- IVM, *see* in vitro maturation
- Kit ligand, 201, 205
- laboratory fertilization, risks in, 184
- lactose, non-penetrating CPA, 29
- large volume samples, freezing, 244–245
- late pregnancy loss, 179, 183
- latent heat release, 243
- legal aspects
 embryo cryopreservation, 72, 78
 posthumous disposal of biomaterials, 253–254
 sperm cryopreservation, 43
- liquid nitrogen (LN₂), 41
 contact with, 106, 134, 158
 contamination risk, 98–99, 106, 138–139
 osmotic stress reduction, 12
 storage in, 146–147
 tissue destruction by, 1
- liver cryopreservation, 245–246
- LN₂, *see* liquid nitrogen
- long-term storage
 ART outcome, 184
 ethical issues, 251
- low birthweight, ART and, 184
- lutinizing hormone (LH), 200–201
- macromolecules, CPAs, 30–31
- magnetic separation immunoassay analysis, 207
- malignancy, *see* cancer patients
- malignancy residual disease, *see* minimal residual disease (MRD)
- maltose, 29
- mannose, 29
- masturbation, 41, 58, 248–249
- maternal age
 ART outcomes, 80, 125–126, 178
 late pregnancy loss, 179
 oocyte donation needed, 169
- maternal ill-health, ART outcomes, 184
- McGill Cryoleaf
 efficacy of, 148, 148–150
 illustrated, 146, 147
 oocyte thawing, 147–148
 oocyte vitrification, 144–145
 vitrification, 146
- McGill protocols, 147–148, 150–153
- mechanical isolation, of follicles, 201–204
- medical practitioners, influence of, 249
- meiotic spindle, 145, 148, 172

Index

- membranes, *see* cell membranes
 menstrual cycle, natural, 101
 mental competence, in consent, 250, 251, 252–253
 MESA (microsurgical epididymal sperm aspiration), 41, 42–43, 52
 metaphase II, *see* MII
 methanamide, 26
 methanol, 27
 methyl sulfoxide, *see* dimethyl sulfoxide
 microbial contamination risk, in vitrification, 158
 microdissection for testicular sperm extraction (Micro-TESE), 53
 microscopy
 frozen–thawed oocytes, 123–124
 MII spindle maintenance, 125
 microsurgical epididymal sperm aspiration (MESA), 41, 42–43, 52
 microtubule depolymerization, 172
 microvacuolization, 124
 MII oocytes
 ovarian tissue autotransplantation, 194
 rapid freezing, 157–158
 spindle damage, 122, 124–125
 MII oocytes (mouse)
 aquaporin 3 expression, 17–18
 CPA permeability, 18–20
 water movement pathway, 17
 minimal residual disease (MRD)
 monitoring, 226, 228
 risk
 ovarian tissue grafts, 252
 testicular tissue cryopreservation, 250
 use of SSCs, 62
 whole ovary grafts, 195
 minimum volume cooling protocol, 172–173
 miscarriage, 178–179, 182
 molality, 3
 molarity, 3
 monoethylene glycol (MEG), *see* ethylene glycol
 monosaccharides, 28–29
 MOPS-buffered media, 139
 moral objections
 to egg donation, 175
 to embryo cryopreservation, 251
 morulae (mouse)
 CPA permeability, 18, 19, 20
 cryopreservation procedures, 16
 water movement pathways, 17, 18
 morulae cryopreservation, 21
 motherhood postponed, 153
 oocyte cryopreservation, 114, 131–132, 174–175, 178
 oocyte vitrification, 142
 mother-to-daughter oocyte donation, 152–153
 mouse developmental stages, 16–22
 MRD, *see* minimal residual disease
 multigestation pregnancies, 67, 181, 184
 avoidance, 67–68, 89
 legal restrictions on, 76
 rates of, 181
 Multi-Thermal-Gradient (MTG) device, 235, 237, 244–245
 musculoskeletal abnormalities, 180, 183
 neonatal outcomes, ART babies, 149–150, 182, 184
 neovascularization, ovarian tissue grafts, 233
 nitrogen
 see also liquid nitrogen
 slush device, 132–134
 non alkylating agents, 57–58
 non-aseptic vitrification, 108–109, 160
 non-biological carriers, 54
 non-malignant systemic diseases, 40
 non-penetrating cryoprotectants, 26, 28–31, 76
 in thawing, 78
 slow-cooling cryopreservation, 121, 122
 vitrification, 140
 non-penetrating polymer, 13
 non-vitrifying solutions, 108, 109–110
 nucleation, ice formation, 2
 nucleoli, zygote quality, 161
 obstetric outcomes
 oocyte cryopreservation, 132, 178, 184
 singleton pregnancies, 181–182
 OHSS, *see* ovarian hyperstimulation syndrome
 oligoathenoteratozoospermia, 42
 oligozoospermia, 48, 57–58
 oncology, *see* cancer patients
 oocyte cryopreservation, 69, 114–115, 117, 128
 advantages of, 144
 cell membrane permeability, 16–17
 concerns about, 120
 cooling rate, 77
 CPA permeability, 20–21, 30, 139
 damage during, 16, 31–32
 developmental stage, 116–117
 history, 114–115, 121–122, 132
 indications for, 120, 131–132, 157–158
 legal issues, 251–252
 new developments, 122–123
 outcomes
 effectiveness, 125, 191
 implantation rate, 126
 in cancer patients, 251–252
 perinatal risks, 178, 184
 pregnancy, 182–184, 185
 ownership and disposition, 253–254
 publications, 126
 quality, 123, 124–125
 MII spindle in, 125
 ovarian tissue graft sites, 220
 pronuclei in, 158
 safety, 127–128, 184
 slow cooling, 10, 115–116, 120–121, 172
 slow cooling vs. vitrification, 145, 148
 social and cultural effects, 174–175
 treatment delay in cancer patients, 251
 unfertilized, 69–70
 volume change measurement, 17
 water movement, 20–21
 young patients, 251–252
 see also oocyte vitrification
 oocyte donation, 114, 169–170, 174
 donor selection, 170–171
 donor stimulation, 171
 mother-to-daughter, 152–153
 oocyte vitrification, 172
 restrictions on, 175
 oocyte retrieval
 in unstimulated menstrual cycle, 144–145
 McGill Cryoleaf protocol, 148–150, 151
 transvaginal follicular aspiration, 171
 oocyte thawing
 in donor program, 173
 McGill Cryoleaf protocol, 147
 oocyte vitrification, 115, 116, 131–132, 142, 153
 advantages/disadvantages, 146, 172
 at GV stage, 160
 breast cancer patients, 151
 cooling rate, 134
 CPAs in, 84, 145
 developments in, 144–145
 donor programs, 169–170, 171, 172, 175–176
 advantages, 172
 outcomes, 174
 history, 145

Index

- McGill Cryoleaf protocol, 144–145, 146
- outcomes, 175
- neonatal, 149–150
 - protocols compared, 127
 - risks, 178
 - success rates, 137
- principles of, 145
- solutions for, 139–141
- oocyte-derived factors, 200–201
- oocytes
- evaluation of, 123–124, 161, 206
 - folliculogenesis, 200–201, 208–209
 - in vitro aging, 127
 - membrane permeability, 10–11, 21
 - nucleus counting, 206
 - numbers thawed, 126
 - reserve, 189
 - see also* germinal vesicle oocytes
- oocytes (animal)
- polymer CPAs, 30
 - sugars as CPAs, 29
- oocytes (mouse)
- CPA permeability, 18–20, 26–27
 - non-penetrating CPAs, 30
 - water movement pathway, 17
- oophorectomy, for ovary
- cryopreservation, 237, 238
- open pulled straw (OPS), 132, 133
- cooling/warming rates, 135–137
 - in CSS development, 158
 - oocyte vitrification, 133
- organ transplantation, 241
- orthotopic transplantation
- ovarian tissue, 192–193, 218–219
 - surgical techniques, 223
 - sites for, 220, 223–225
- osmosis, 4
- osmotic pressure, extracellular, 4
- osmotic shock, prevention, 28
- osmotic shrinkage, 16
- osmotic stress, 12, 162–163
- osmotic swelling, cryodamage, 16
- outcomes,
- aseptic vitrification, 109
 - classic technique, 115, 116
 - embryo cryopreservation
 - developmental stages at, 81–82, 91–92
 - live birth rates, 72, 81–82 - embryos
 - implantation, 81
 - transfer, 80–81 - GV stage oocyte cryopreservation, 116–117
 - in vitro culture post-thawing, 161
- McGill Cryoleaf vitrification
- protocol, 148, 148–150
- obstetric, adverse, 182
- oocyte cryopreservation, 115–116, 125, 132
- protocols compared, 127
- oocyte vitrification, 116, 137, 175
- in donor program, 174
- ovarian tissue transplantation, 193
- slow-freezing technique, 83, 91–92, 115–116
- sperm donation, 48
- success rates
- embryo transfer, 80–82
 - oocyte vitrification, 137
- sucrose in slow-freezing solutions, 115–116
- vitrified vs. slow-freezing technique, 83
- see also* pregnancy outcomes
- ovarian cortex, 200, 206, 213
- ovarian cortical tissue
- culture, 206
 - primordial follicle activation, 207
 - two-step system, 205–206
- follicles from, 201
- handling, 222
- in vitro culture, 201–204
- ovarian function, 200–201
- ovarian hyperstimulation syndrome (OHSS)
- embryo cryopreservation need, 68, 78–79, 89
 - risk in stimulation protocols, 79, 144–145, 175
- ovarian neoplasm, 151
- ovarian stem cells, 213–214
- ovarian stimulation, 67, 171, 184
- in breast cancer, 151
 - outcomes, 81–82
- ovarian tissue, 201, 208, 252
- ovarian tissue cryobanking, 213–214
- indications for, 221–222
 - outcomes, 214–216
 - procedure safety, 226–229
 - storage protocol, 221–222, 226
 - transportation, 213
- ovarian tissue cryopreservation, 189, 196, 242
- cancer patients, 191, 252–253
 - disadvantages, 144
 - for transplantation, 219–220
 - histological analysis, 216
 - in vitro culture, 214
 - indications for, 190
 - minimal residual disease risk, 144, 229
 - ownership and disposition, 253–254
 - protocol, 191, 214–216, 222
 - young patients, 252–253
- ovarian tissue transplantation,
- 191–195, 218, 219–220
 - autotransplantation, 191–195, 227
 - clinical cases, 227
 - cortical pieces, 192
 - endocrine monitoring, 224
 - functional lifespan, 225, 233, 241–242
 - heterotopic, 193–194
 - history, 218–219, 220
 - indications for, 218, 221–222
 - ischemia, 241–242
 - orthotopic, 192–193
 - patient evaluation, 222
 - patient monitoring, 226
 - protocols/procedures, 223
 - publications, 218
 - sites for, 218–220, 220, 223
 - success factors
 - surgical techniques, 223
 - xenografting, 191
- ovarian vasculature, graft sites, 225
- ovary (whole)
- as graft site, 223
 - culture, 204
 - heat transfer, 242–243
- ovary (whole) cryopreservation, 233–234, 238, 242
- animal models, 234–236, 245–248
 - directional freezing, 244–245
 - follicular viability, 237
 - heat transfer difficulties, 242–243, 244–245
 - human studies, 238
 - pregnancies after, 215
 - protocols, 195, 236–238
 - recent developments, 242
- ovary (whole) transplantation, 194–195, 220, 241, 245
- ovary (whole) with vascular pedicle
- cryopreservation, 234–236
 - advantages in, 233
 - animal models, 233–236
 - CPA perfusion, 194
 - transplantation, 194–195, 234
- parental consent
- embryo cryopreservation, 251
 - oocyte cryopreservation, 252
 - ovarian tissue cryopreservation, 252–253
 - sperm banking, 249
 - patient evaluation, pre-transplant, 222

Index

- patient monitoring, post-transplant, 226
- pelvic imaging, 226
- pelvic peritoneum, graft sites, 223–225
- penetrating cryoprotectants, 4–7, 24–28
- embryo cryopreservation, 76, 139
- oocyte cryopreservation, 121, 139, 145
- oocyte vitrification, 140
- percutaneous epididymal sperm aspiration (PESA), 41, 52
- permeability, *see* cell membrane permeability
- PG, *see* 1,2-propanediol
- pH difference, physiological solutions, 139
- phase diagram for CPAs, 12–14
- phosphate-buffered saline (PBS), 123, 139
- physiological solutions, in vitrification, 139
- plasma membranes, *see* cell membranes
- polarized light microscopy, 125
- Polyscope, 125
- polycystic ovary syndrome (PCOS), 109, 144–145, 179
- polyethylene glycol (PEG), 30
- polymerase chain reaction, real-time 207, 227
- polymers, 13, 30–31, 145
- polyols, 27–28
- polysaccharides, 28, 29–30
- polyvinyl alcohol, 31
- polyvinylpyrrolidone, 30–31
- posthumous disposal of biomaterials, 253–254
- posthumous sperm retrieval, 51
- post-insemination time, embryo transfer outcomes, 80
- postpubertal females, 250–252
- postpubertal males, 248–249
- pre-antral follicles, 204, 207–208
- pre-freeze stage, 76–77
- pregnancy outcomes
- embryo cryopreservation, 89, 90, 95
- embryo implantation and, 81
- hormone replacement for support, 147
- oocyte cryopreservation, 182–184, 185
- ovarian cryopreservation, 215
- ovarian tissue cryobanking, 214–216
- ovarian tissue transplantation, 192–193, 220
- pregnancy rates
- blastocyst stages, 160, 164
- cryopreservation complications, 42–43
- embryo stages, 81–82, 83
- oocyte cryopreservation, 127
- oocytes, 251–252
- pronuclear integrity and, 163
- testicular sperm, 54
- vitrification protocols, 83, 148–150, 160
- pre-implantation genetic diagnosis (PGD), 79, 89, 102
- blastocyst cryopreservation, 102
- embryo biopsy, 82
- pronuclear stage cryopreservation, 79
- pre-implantation stage, embryo cryopreservation protocol, 69
- premature ovarian failure (POF)
- chemotherapy-induced, 189, 196
- oocyte donation needed, 169
- ovarian cryobanking need, 221
- ovarian tissue cryobanking need, 190, 218
- radiotherapy-induced, 189–190
- prepubertal boys, 59–61, 249–250
- prepubertal girls, 252–253
- prepubertal ovaries, follicle source, 201
- preterm delivery, ART and, 184
- primordial follicles
- activation of, 204–205
- assessment, 222
- in vitro culture, 195, 200, 204–205, 207, 208
- in vivo development, 200–201
- progesterone, 207
- PROH, *see* 1,2-propanediol
- pronuclear integrity, 161, 163
- pronuclear membranes, 161
- pronuclear stage embryo
- cryopreservation, 69–70, 76–78, 157–158
- comparative studies, 81–82, 96
- cooling rate, 77
- cryodamage, 70
- developmental stage and outcomes, 81–82
- freezing stage, 77, 78
- indications for, 78–80
- morphological evaluation, 161–163
- scoring system and outcome, 161, 162, 163
- selection for, 77
- thawing, 77
- timing in, 77
- vitrification, 82–84
- pronuclear vs. early cleavage stages, embryo transfer, 82
- pronuclear zygotes, *see* pronuclear stage
- embryo cryopreservation
- pronuclei, oocyte and embryo evaluation, 158
- 1,2-propanediol (PROH, propylene glycol), 18, 27
- combined CPAs, 13–14, 139
- embryo cryopreservation, 68–69, 76, 139
- oocyte cryopreservation, 122, 145
- oocyte vitrification, 139
- properties of, 7
- structure, 6
- toxicity, 31–32, 122
- vitrification solutions, 139, 146
- in water movement pathways, 20
- propylene glycol, *see* 1,2-propanediol
- protein macromolecules/polymers, 30, 33
- psychogenic anejaculation, 48–49
- publications
- on carrier devices, 134–135
- on in vitro follicular culture, 202–213
- on oocyte cryopreservation, 126, 132
- on vitrification, 131
- quality of life
- cancer survivors, xi
- cancer treatment planning, 58–59
- childhood cancer management, 58
- radioimmunoassay, 207
- radiotherapy, gonadotoxicity, 40, 189–190
- raffinose, 29
- rapid freezing, 157–158, 173
- see also* ultra-rapid cooling;
- vitrification
- real-time polymerase chain reaction, 207, 227
- recipient preparation, *see* endometrial preparation
- recrystallization, in thawing period, 243–244
- rehydration, during warming, 121
- rejection, of graft, 241
- religious issues, embryo disposal, 255
- research, embryo donation for, 254–255
- retrograde ejaculation, semen collection, 49
- revascularization, grafted ovarian tissue, 191, 219

- safety
 carrier devices, 138–139
 embryo cryopreservation, 72
 embryo vitrification, 84
 oocyte cryopreservation, 132
 ovarian tissue cryobanking, 226–229
 ovarian transplantation, 195–196
 Sage IVF Vitrification Warming Kit, 141
 secondary follicle culture, 200
 semen cryopreservation
 boys, 58–59
 donor program, 47, 48
 seminiferous tubules
 sperm retrieval from, 52–53
 spermatogenesis in, 60
 SSC transplantation, 59–61
 semipermeable membranes, water transportation, 4
 sequential culture, for blastocysts, 96–97
 Sertoli cells, 60, 61
 serum in culture media, 204
 sexually transmitted infections, 47
 shared egg donation, 169
 shrinkage (artificial), of blastocele, 99–100, 101
 simple diffusion, *see* diffusion (simple)
 single embryo transfer (SET), 67, 68
 single women, 174–175
 single-phase culture, 96–97
 singleton pregnancies, 181
 slow-freezing cryopreservation, 10, 157
 blastocysts, 69, 97, 99
 CPA phase diagram, 12–14
 donor program, 48
 embryos, 69
 cleavage stage, 70
 days 3/4, 91–92
 pronuclear stage, 76–77, 83
 thawing, 92
 Multi-Thermal-Gradient system, 244–245
 oocytes, 115–116, 120–121, 127
 osmotic stress reduction, 12
 ovarian tissue, 191, 215
 solutions for, 115–116
 sperm, 42, 41
 testicular tissue, 59
 time factors, 131
 vitrification compared, 83, 99, 102, 127
 whole organs, 243
 whole ovary, 237, 242–243
 whole ovary with vascular pedicle, 234–236
 social effects, oocyte cryopreservation, 174–175
 social reasons for fertility preservation
 sperm cryopreservation, 39, 40
see also motherhood postponed
 sodium-free freezing media, 126
 classic technique, 116
 MII spindle maintenance, 124–125
 slow-freezing protocols, 122–123
 solubility, 3–4
 solutes
 concentration in cryoinjury, 4
 in aqueous solutions, 3
 membrane permeability to, 10–11
 solution effects, in cryopreservation, 12, 122–123
 solutions, in vitrification, 134, 146
 solvents, 3–4
 sperm
 abnormal, 42
 collection, 41
 informed consent for, 248–249
 techniques, 51–53, 54, 58
 morphology, 42
 motility, 42
 sperm (animal) cryopreservation
 breeding programs, 39–40
 CPAs, 26
 damage by, 32
 non-penetrating
 monosaccharides, 29, 28
 polymers, 31
 sugars, 28–30
 penetrating
 alcohols, 27, 28
 formamide, 26
 sperm cryobanking
 ethical considerations, 248–249
 in China, 46–48
 sperm cryobanks
 sperm cryopreservation, 40, 43, 62–63
 adverse effects, 42–43
 boys with cancer, 58–59
 clinical applications, 40
 complications, 42–43
 contraindications, 42
 donor programs, 46, 48
 history, 39, 95
 ownership and disposition, 253–254
 protocols, 40–41
 quality of sperm, 42, 48, 54
 quantity of sperm, 42
 retrieval techniques, 51–53
 electroejaculation, 48–49
 surgically retrieved, 51, 53
 viability, 42
 vitrification, 41, 84
 sperm donation
 cryopreservation in, 46, 48
 follow-up results, 48
 sperm donors, selection/screening, 46–48
 spermatids, in ICSI, 58
 spermatocytes, in ICSI, 58
 spermatogenesis
 restoration, 61–62
 SSCs in, 60
 spermatogonial stem cells, *see* SSC
 spermatozoa, vitrification, 160
 spinal cord injury, 48–49, 53
 spindle malformation, 144, 145
 SSC (spermatogonial stem cells), 59, 62–63
 in spermatogenesis, 60
 in vitro culture, 61
 isolation and purification, 61–62
 testicular tissue cryopreservation, 61–62
 transplantation, 59–61
 stage-specific markers, follicular growth, 206–207
 stem cells,
 ovarian, 213
see also embryonic stem cells; SSC
 spermatogonial stem cells
 stimulation protocols, oocyte donation, 171
 storage, *see* cryobanking
 straws, *see* cryopreservation straws; cut standard straws (CSS)
 subcutaneous sites, for grafts, 223–225
 subfertility, male, 42
 sucrose, 29, 140
 blastocyst vitrification, 164
 clinical efficacy, 124, 126–127
 concentrations, 122
 embryo cryopreservation, 68
 in CPA mixture, 139
 MII spindle maintenance, 124–125
 oocyte cryopreservation, 115–116, 122, 123, 145
 oocyte vitrification, 140
 osmotic stress reduction, 12
 slow-freezing solutions, 12, 115–116, 122
 sodium-free freezing media, 123
 sugars, 28–30
 sulfoxide cryoprotectant, *see* dimethyl sulfoxide
 supercooling, 2–3, 99, 243
 supplements to culture media, 204–206
 surgery
 on male genitalia, 40
 ovarian tissue grafts, 223

Index

- surgically retrieved sperm, 41, 51, 53
 survival rates
 childhood malignancies, 57
 cryopreserved oocytes, 127, 147, 174
 systemic autoimmune rheumatic diseases, 151–152
 systemic lupus erythematosus, 151–152
 SYTOX dye, 206–207

 temperature
 and equilibration time, 7
 in CPA permeability, 12
 in CPA toxicity, 7, 31–32
 measurement, 2
 nature of water and, 2
 solubility and, 3–4
 transportation to cryobank, 213
 water movement pathways, 16, 17
 temperature gradient
 cooling rate, 243
 cooling rate and ice formation, 11
 directional freezing, 244–245
 glass transition (*T_g*), 2–3
 in cooling and warming, 12
 in slow-cooling method, 121
 ultra-rapid warming, 159
 testicular sperm, 52–53, 54
 testicular sperm aspiration (TESA), 52
 testicular sperm extraction (TESE), 52–53
 testicular tissue
 ownership and disposition, 253–254
 sperm retrieval from, 52–53
 SSC numbers, 61–62
 testicular tissue (animals), 60–61
 testicular tissue cryopreservation, 63–58
 ethical issues, 62, 249–250
 for prepubertal boys, 40, 59, 249–250
 problems with, 61–62
 SSC transplantation, 59–61
T_g (glass transition temperature), 2–3
 thawing
 aseptic vitrification and, 110
 blastocysts, 100, 101, 108
 donor program, 173, 174
 embryos, 77–78, 91–92
 non-aseptic vs. aseptic cooling, 108
 oocytes, 126, 147–148, 174
 recrystallization in, 243–244
 slow-freezing technique, 91
 vitrification and, 100, 174
 whole ovary with vascular pedicle, 234, 235
 thawing medium, 147
 thermal gradient, *see* temperature gradient

 tissue handling, ovarian
 cryopreservation, 222
 tools, *see* embryo carrier devices
 toxicity, *see* CPAs, toxicity
 transforming growth factor- β superfamily, 200–201
 transmission electron microscopy, 206
 transplantation
 environmental factors in results, 220
 history, 241
 see also heterotopic transplantation;
 orthotopic transplantation;
 ovarian tissue transplantation;
 ovary (whole) transplantation
 transportation, 84, 213
 transvaginal follicular aspiration, 171
 treatment delay, cancer patients, 251
 trehalose, 29
 TUNEL labeling, 206
 Turner syndrome, 152–153, 169
 two-stage consenting process, 250
 two-step culture system, 205–206, 208
 two-step vitrification, 21

 UK
 consent for minors, 249, 250
 oocyte cryopreservation, 253
 sperm donor anonymity, 47
 ultra-rapid cooling, 106, 108, 111
 ultra-rapid warming, 159
 urinary tract inflammations, 49
 urine alkalinization, 49
 urogenital reconstructive surgery, 51
 USA
 consent for minors, 249, 250
 oocyte cryopreservation, 252
 sperm donor screening/testing, 47
 uterine dysfunction, after radiotherapy, 189

 vacuolization
 of embryos, 163
 of oocytes, 174
 vascular pedicle, intact ovary and, 194–195, 216
 vascular surgery, development of, 241
 vascular transplantation, whole ovary, 194–195
 Vero cells, co-culture, 95
 vibratory stimulation, 53
 viral agents, in cryostorage, 139
 viscosity, 14
 vitamin E, antioxidant treatment, 220
 Vitmaster, 132–134
 vitreous state, 11
 vitrification, 131
 advantages, 11, 146

 aneuploidy, 148
 aseptic, 106–107
 blastocysts, 95, 97–99
 aseptic, 106–107
 CPAs, 21, 99
 slow-freezing compared, 99
 water movement, 21
 closed systems, 84
 CPA damage, 12–14
 CPA movement, 20–21
 developments in, 157–158
 disadvantages, 146
 embryos, 69
 CPAs, 20–21
 day 3 and day 4, 92
 pronuclear stage, 77, 82–84
 water movement, 20–21
 equilibration in, 7
 GV stage oocytes, 117
 ice crystal prevention, 11
 McGill Cryoleaf procedure, 146
 morulae, 21
 one-step treatment, 21
 oocytes, 115, 116, 127
 ovarian tissue, 215
 probability of, 11, 131
 process of, 2, 3
 pronuclear stage embryos, 69–70, 83
 publications on, 131
 relationship of conditions for, 14
 sperm, 41
 for donor program, 48
 two-step treatment, 21
 variables influencing effectiveness, 11
 vs. ice crystals, optical differences, 12
 vs. slow freezing, 102
 water movement, 20–21
 whole ovary with vascular pedicle, 234–236, 235, 131
 see also embryo carrier devices;
 vitrification carrier devices
 vitrification carrier devices, 92, 131, 146
 blastocysts, 97, 100
 oocytes, 132–135
 vitrification solutions
 for oocytes, 139–141
 McGill Cryoleaf protocol, 146–147
 McGill Cryoleaf vitrification, 146
 scientific disclosure, 140
 vitriplug hemi-straw embryo carrier, 107
 Vitrisafe, 107, 110
 volume changes, measurement, 16

warming	nature of, 2	young boys, fertility cryopreservation,
after slow cooling, 121	properties in cryopreservation,	58, 249–250
aseptic vitrification, 159, 160	24	young cancer patients, <i>see</i> cancer
carrier devices and, 135–137	water movement pathways, <i>see</i> channel	patients, young patients
phase diagram for CPAs, 12–14	diffusion; diffusion (simple);	young men, SSC transplantation,
Sage IVF Vitrification Warming Kit,	osmosis	59–61
141	water permeability, 10–11,	
vitrification protocols, 92	16, 21	zona pellucida
conditions for, 14	whole ovary cryopreservation,	breach, 138, 164
effectiveness, 137–138	<i>see</i> ovary (whole)	hardening, 174
solutions, 140–141	cryopreservation	manipulation, 80–81, 102
water		zygotes
glass transition, 2–3	xenogeneic germ cell transplantation,	cryodamage, 70
intracellular, 1	59	initial score, 162
reduction by CPAs, 26	xenografting, 191, 219–220	selection, 71